Go-ahead for PledPharma to Proceed With PLIANT Study Patient Recruitment  
2/26/2013 11:25:52 AM

Stockholm, 2013-02-26 09:42 CET (GLOBE NEWSWIRE) -- DSMB has analyzed the test results from the first patient that was enrolled in the study two weeks ago. The study is in the initial stage, the so-called dose-escalation phase. The dosages of PledOx follow a strict protocol for when evaluating a new compound for the first time in a clinical trial. With the approval to proceed with the study, the first patient is to receive the second dose of PledOx, while the next two patients to be included in the study in parallel can receive the first low dose of PledOx. When all three patients received at least one cycle of therapy, and the first patient received three cycles DSMB will re-evaluate the data to give approval for this procedure to be repeated for the higher dose of PledOx.